Chemokines and chronic heart allograft rejection [3]

Transplantation

Volumn 84, Issue 3, 2007, Pages 442-444

  Smith, R Neal ^a   Ueno, Takuya ^a   Ito, Toshiro ^a   Tanaka, Katsunori ^b   Shea, Susan P ^a   Abdi, Reza ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3;

CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; HEART MUSCLE CONTRACTILITY; INFLAMMATION; LETTER; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHEMOKINES; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEART TRANSPLANTATION; MICE; MICE, KNOCKOUT; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547882749     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000277535.02541.30     Document Type: Letter

References (21)

1. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975.
2. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12: 511.
3. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515.
4. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15: 479.
5. Kobayashi H, Novick AC, Toma H, Fairchild RL. Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class IIMHC disparate skin allografts. Transplantation 2002; 74: 387.
6. Fairchild RL, VanBuskirk AM, Kondo T, Wakely ME, Orosz CG. Expression of chemokine genes during rejection and longterm acceptance of cardiac allografts. Transplantation 1997; 63: 1807.
7. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
8. Furukawa Y, Mandelbrot DA, Libby P, Sharpe AH, Mitchell RN. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am J Pathol 2000; 157: 473.
9. Sho M, Harada H, Rothstein DM, Sayegh MH. CD45RB-targeting strategies for promoting long-term allograft survival and preventingchronic allograft vasculopathy. Transplantation 2003; 75: 1142.
10. Akashi S, Sho M, Kashizuka H, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005; 80: 378.
11. Kosuge H, Haraguchi G, Koga N, Maejima Y, Suzuki J, Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 2006; 113: 2613.
12. Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005; 79: 1215.
13. Ruster M, Sperschneider H, Funfstuck R, Stein G, Grone HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol 2004; 61: 30.
14. Yun JJ, Whiting D, Fischbein MP, et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 2004; 109: 932.
15. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105: 35.
16. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 1199.
17. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391.
18. Tung TH, Mackinnon SE, Mohanakumar T. Combined treatment with CD40 costimulation blockade, T-cell depletion, low-dose irradiation, and donor bone marrow transfusion in limb allograft survival. Ann Plast Surg 2005; 55: 512.
19. Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl Immunol 2004; 13: 117.
20. Wang CY, Mazer SP, Minamoto K, et al. Suppression of murine cardiac allograft arteriopathy by long-term blockade of CD40-CD154 interactions. Circulation 2002; 105: 1609.
21. Shirasugi N, Adams AB, Durham MM, et al. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism-and nonchimerism- inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169: 2677.